Kathryn Heimer, APRN
Family · Cheyenne, WYNPI 1609060524
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,070 of the $4,882 with a category attached, or 83.4%. It is spread thinly across 27 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,448 and has fallen 73.7% since, to $382 in 2025. Among family clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$877
- Teleflex LLC$660
- Sumitomo Pharma America, Inc.$493
- Johnson & Johnson$471
- Pfizer$350
- Myovant Sciences Inc.$241
- plus $2K from 21 others
What the payments were for
- Travel & lodging$2936%
- Food & beverage$4,07083%
- Education$52011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 30 | $877 |
| Teleflex LLC | 5 | $660 |
| Sumitomo Pharma America, Inc. | 22 | $493 |
| Johnson & Johnson | 18 | $471 |
| Pfizer | 18 | $350 |
| Myovant Sciences Inc. | 13 | $241 |
| Bayer | 10 | $207 |
| Dendreon Pharmaceuticals LLC | 12 | $206 |
| Accord Healthcare, Inc. | 12 | $204 |
| Blue Earth Diagnostics | 8 | $186 |
| AbbVie(2 entities) | 11 | $176 |
| Sunovion Pharmaceuticals Inc. | 10 | $157 |
| Merck | 7 | $157 |
| Novartis | 3 | $64 |
| Progenics Pharmaceuticals, Inc. | 2 | $64 |
| 180 Medical, Inc. | 3 | $61 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $59 |
| Endo Pharmaceuticals Inc. | 3 | $45 |
| Convatec Inc. | 1 | $41 |
| Boston Scientific | 1 | $32 |
| Coloplast | 2 | $31 |
| Rochester Medical Corporation | 1 | $24 |
| Palette Life Sciences, Inc. | 1 | $24 |
| Dentsply IH Inc. | 1 | $17 |
| Ambu Inc. | 1 | $13 |
| Tolmar Pharmaceuticals, Inc. | 1 | $12 |
| Myriad Genetic Laboratories, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$618
How this compares
$4,882 in reported general payments places this provider in the 95th percentile of 284 family providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 174 | $133,404 |
| GemtesaVibegron | 45 | $28,987 |
| Tamsulosin Hcl | 358 | $9,650 |
| Methenamine Hippurate | 96 | $8,194 |
| Potassium Citrate ErPotassium Citrate | 31 | $4,494 |
| Testosterone | 13 | $4,262 |
| Finasteride | 255 | $3,777 |
| Estradiol | 35 | $2,739 |
| Oxybutynin Chloride ErOxybutynin Chloride | 53 | $1,480 |
| Dutasteride | 28 | $1,168 |
| Trimethoprim | 19 | $985 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 48 | $831 |
| Cephalexin | 77 | $761 |
| Fluticasone Propionate | 16 | $316 |
| Levothyroxine Sodium | 22 | $302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $877 | $133,404174 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $493 | $28,98745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 284 family providers in Wyoming.
Other family in Cheyenne
- Jill GiranyCheyenne$44K
- Greta SkagenCheyenne$4K
- Jennifer DavisCheyenne$4K
- Anne BarnesCheyenne$4K
- Katherine BrockCheyenne$3K
- Lana SykesCheyenne$3K
- Sheriedan GrannanCheyenne$3K
- Shala SwarmCheyenne$2K
- Heather RobertsCheyenne$2K
- Kristi RoybalCheyenne$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.